Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 61 of 99

  1. NN1471-5026

    NovoThirteen

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  2. NN1471-7712

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  3. NN1644-7794

    NovoThirteen

    Type 1 diabetes mellitus

    phase 1 other active

    1 trial

  4. NN1644-8194

    NovoThirteen

    Diabetes type 1

    phase 1 other active

    1 trial

  5. NN1679-8505

    NovoThirteen

    Healthy participants and participants with type 2 diabetes

    phase 1 other active

    1 trial

  6. NN6019-7853

    NovoThirteen

    transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM)

    phase 1 other active

    1 trial

  7. NN6022-7683

    NovoThirteen

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  8. NN6497-8309

    NovoThirteen

    Type I diabetes

    phase 1 other active

    1 trial

  9. NN6497-8316

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  10. NN6537-7650

    NovoThirteen

    Heart Failure

    phase 1 other active

    1 trial

  11. NN6582-4838

    NovoThirteen

    Healthy Volunteers

    phase 1 other active

    1 trial

  12. NN6705-8141

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  13. NN6706-8230

    NovoThirteen

    Healthy volunteers, treatment for heart failure

    phase 1 other active

    1 trial

  14. NN7442-7582

    NovoThirteen

    Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.

    phase 1 other active

    1 trial

  15. NN7442-8454

    NovoThirteen

    Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.

    phase 1 other active

    1 trial

  16. NN7614-7656

    NovoThirteen

    Hereditary haemochromatosis (HH) type 1

    phase 1 other active

    1 trial

  17. NN9388-7782

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  18. NN9490-7611

    NovoThirteen

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

  19. NN9490-8151

    NovoThirteen

    Participants with obesity, but otherwise healthy

    phase 1 other active

    1 trial

  20. NN9490-8152

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  21. NN9490-8156

    NovoThirteen

    hepatic impairment

    phase 1 other active

    1 trial

  22. NN9541-4922

    NovoThirteen

    Healthy postmenopausal females (Type 2 Diabetes)

    phase 1 other active

    1 trial

  23. NN9541-4923

    NovoThirteen

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  24. NN9541-7760

    NovoThirteen

    Type 2 diabetes mellitus

    phase 1 other active

    1 trial

  25. NN9541-8116

    NovoThirteen

    Obesity, Type 2 Diabetes with either overweight or obesity

    phase 1 other active

    1 trial

  26. NN9733-8133

    NovoThirteen

    Healthy Participants and Participants with type 2 diabetes

    phase 1 other active

    1 trial

  27. NN9833-8285

    NovoThirteen

    obesity

    phase 1 other active

    1 trial

  28. NN9833-8421

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  29. NN9838-4695

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  30. NN9838-8411

    NovoThirteen

    Obesity, CCI, CCI

    phase 1 other active

    1 trial

  31. NNC 0172-0000-2021

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    phase 1 small molecule completed

    1 trial

  32. NNC0480-0389

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  33. NP-G2-044

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  34. NP101

    Teva Pharma GmbH

    Compare Bioequivalence Patches Previously Used in the NP101-007 Study

    phase 1 small molecule completed

    1 trial

  35. NPC-22

    Belpharma s.a.

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial

  36. NPC-22

    Belpharma s.a.

    Safety and Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  37. NRS-033

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  38. NT-301 1 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tolerability of NT-301 Nasal Spray

    phase 1 other completed

    1 trial

  39. NTC-001

    BioNTech SE

    Metastatic melanoma

    phase 1 other active

    1 trial

  40. NTQ5082 capsule

    Nanjing Chia-tai Tianqing Pharmaceutical

    Complement-mediated Hemolytic Diseases

    phase 1 small molecule active

    1 trial

  41. NUC-011/BIO

    Dr. Falk Pharma GmbH

    Primary Sclerosing Cholangitis (PSC)

    phase 1 other active

    1 trial

  42. NX-1607

    Nurix Therapeutics

    Ovarian Cancer, Epithelial

    phase 1 small molecule active

    1 trial

  43. NX-2127

    Nurix Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 1 small molecule active

    1 trial

  44. NX-5948

    Nurix Therapeutics

    Healthy Volunteer

    phase 1 small molecule active

    2 trials

  45. NX210c

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Elderly

    phase 1 small molecule completed

    1 trial

  46. NXP800 in subjects with Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma

    phase 1 other active

    1 trial

  47. NXPTEGO/23/P1-4

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Multiple Sclerosis

    phase 1 other active

    1 trial

  48. NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

    Chongqing Precision Biotech Co., Ltd

    Bone Sarcoma

    phase 1 mab active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.